Encellin

San Francisco, United States Founded: 2015 • Age: 11 yrs
Developer of regenerative materials
Request Access

About Encellin

Encellin is a company based in San Francisco (United States) founded in 2015 by Crystal Nyitray.. Encellin has raised $18.45 million across 4 funding rounds from investors including Khosla Ventures, Y Combinator and SV Latam Capital. Encellin offers products and services including ENCRT. Encellin operates in a competitive market with competitors including Organogenesis, Sofregen, BioTissue, Reapplix and Acera Surgical, among others.

  • Headquarter San Francisco, United States
  • Founders Crystal Nyitray
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Medical Devices & Diagnostics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $18.45 M (USD)

    in 4 rounds

  • Latest Funding Round
    $9.94 M (USD), Series A

    Sep 20, 2023

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Encellin

Encellin offers a comprehensive portfolio of products and services, including ENCRT. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Implant that encapsulates cells to deliver therapeutics for chronic diseases.

People of Encellin
Headcount 1-10
Employee Profiles 4
Board Members and Advisors 5
Employee Profiles
People
Steve Boyd
CTO
People
Grace Wei
COO & Co-Founder
People
Crystal Nyitray
CEO & Co-Founder

Unlock access to complete

Board Members and Advisors
people
Mike German
Diabetes Advisor
people
Becky Foster
Advisor
people
Vern Norviel
Advisor
people
Tejal Desai
Technology Expert & Founder

Unlock access to complete

Funding Insights of Encellin

Encellin has successfully raised a total of $18.45M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $9.94 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 4
  • Last Round Series A — $9.9M
  • First Round

    (19 Jul 2019)

  • Investors Count 4
Date Amount Transaction Name Valuation Lead Investors Investors
Sep, 2023 Amount Series A - Encellin Valuation Khosla Ventures
Aug, 2021 Amount Seed - Encellin Valuation Khosla Ventures , SV Latam Capital
Aug, 2019 Amount Seed - Encellin Valuation Y Combinator
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Encellin

Encellin has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Khosla Ventures, Y Combinator and SV Latam Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
Early-stage startups are funded by this venture capital firm.
Founded Year Domain Location
Early-stage startups are accelerated via funding and educational programs.
Founded Year Domain Location
Venture capital firm investing in science and technology startups
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Encellin

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Encellin

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Encellin Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Encellin

Encellin operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Organogenesis, Sofregen, BioTissue, Reapplix and Acera Surgical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Regenerative therapies for wound care are developed and commercialized.
domain founded_year HQ Location
Silk-derived biomaterials are developed for soft tissue repair in surgery.
domain founded_year HQ Location
Regenerative biologic therapies for eye care are developed and provided.
domain founded_year HQ Location
Developer of patch system for wound healing
domain founded_year HQ Location
Synthetic electrospun scaffolds are provided for regenerative medical uses.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Encellin

Frequently Asked Questions about Encellin

When was Encellin founded?

Encellin was founded in 2015 and raised its 1st funding round 4 years after it was founded.

Where is Encellin located?

Encellin is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Who is the current CEO of Encellin?

Crystal Nyitray is the current CEO of Encellin. They have also founded this company.

Is Encellin a funded company?

Encellin is a funded company, having raised a total of $18.45M across 4 funding rounds to date. The company's 1st funding round was a Seed of $500K, raised on Jul 19, 2019.

What does Encellin do?

Encellin is developing regenerative materials using cell transplant therapy. The company has developed cell transplant therapy for treating missing, damaged, or diseased cells and treatment of chronic diseases.

Who are the top competitors of Encellin?

Encellin's top competitors include Organogenesis, GeniPhys and Acera Surgical.

What products or services does Encellin offer?

Encellin offers ENCRT.

Who are Encellin's investors?

Encellin has 4 investors. Key investors include Khosla Ventures, Y Combinator, SV Latam Capital, and Sand Hill Angels.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available